American Association for Cancer Research
15417786mcr140481t-sup-137172_0_supp_2547180_n8543l.pdf (173.85 kB)

Supplementary Figure 1 from A p53/ARF-Dependent Anticancer Barrier Activates Senescence and Blocks Tumorigenesis without Impacting Apoptosis

Download (173.85 kB)
journal contribution
posted on 2023-04-03, 17:10 authored by Vidya C. Sinha, Lan Qin, Yi Li

Loss of ARF results in diminished p53-function and impaired senescence, but does not impact apoptosis.



In response to oncogene activation and oncogene-induced aberrant proliferation, mammalian cells activate apoptosis and senescence, usually via the p53–ARF tumor-suppressor pathway. Apoptosis is a known barrier to cancer and is usually downregulated before full malignancy, but senescence as an anticancer barrier is controversial due to its presence in the tumor environment. In addition, senescence may aid cancer progression via releasing senescence-associated factors that instigate neighboring tumor cells. Here, it is demonstrated that apoptosis unexpectedly remains robust in ErbB2 (ERBB2/HER2)-initiated mammary early lesions arising in adult mice null for either p53 or ARF. These early lesions, however, downregulate senescence significantly. This diminished senescence response is associated with accelerated progression to cancer in ARF-null mice compared with ARF–wild-type mice. Thus, the ARF–p53 pathway is dispensable for the apoptosis anticancer barrier in the initiation of ErbB2 breast cancer, the apoptosis barrier alone cannot halt mammary tumorigenesis, and senescence is a key barrier against carcinogenesis.Implications: Findings in this relevant mouse model of HER2-driven breast cancer suggest that effective prevention relies upon preserving both ARF/p53–independent apoptosis and ARF/p53–dependent senescence. Mol Cancer Res; 13(2); 231–8. ©2014 AACR.

Usage metrics

    Molecular Cancer Research



    Ref. manager